{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:26:38Z","timestamp":1760171198639,"version":"3.37.3"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","funder":[{"DOI":"10.13039\/501100004600","name":"Kyungpook National University Hospital","doi-asserted-by":"crossref","award":["2014"],"award-info":[{"award-number":["2014"]}],"id":[{"id":"10.13039\/501100004600","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000022668","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:01:28Z","timestamp":1602010888000},"page":"e22668","source":"Crossref","is-referenced-by-count":6,"title":["Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-\u03b1 blockers"],"prefix":"10.1097","volume":"99","author":[{"given":"Eon Jeong","family":"Nam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Kee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"R1-20230105","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61 Suppl 3","author":"Sieper","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R2-20230105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R3-20230105","doi-asserted-by":"crossref","first-page":"e3060","DOI":"10.1097\/MD.0000000000003060","article-title":"Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R4-20230105","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R5-20230105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R6-20230105","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R7-20230105","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R8-20230105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R9-20230105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","article-title":"Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R10-20230105","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R11-20230105","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","article-title":"MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor","volume":"71","author":"Machado","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R12-20230105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R13-20230105","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","article-title":"Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab","volume":"46","author":"Baraliakos","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20230105","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R15-20230105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R16-20230105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","article-title":"Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation","volume":"60","author":"Maksymowych","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R17-20230105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","article-title":"ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis","volume":"55","author":"van der Heijde","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230105","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/acr.22869","article-title":"Continuous improvement of physical functioning in ankylosing spondylitis patients by tumor necrosis factor inhibitors: three-year followup and predictors","volume":"68","author":"van Weely","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R19-20230105","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3899\/jrheum.160594","article-title":"Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-alpha Inhibitors for Up to 10 Years","volume":"43","author":"Poddubnyy","year":"2016","journal-title":"J Rheumatol"},{"key":"R20-20230105","first-page":"1609","article-title":"A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI)","volume":"22","author":"Jones","year":"1995","journal-title":"J Rheumatol"},{"issue":"(Suppl 11)","key":"R21-20230105","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R22-20230105","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/ard.2008.092650","article-title":"Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy","volume":"68","author":"Tzelepis","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R23-20230105","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group","volume":"26","author":"van der Heijde","year":"1999","journal-title":"Assessments in Ankylosing Spondylitis J Rheumatol"},{"key":"R24-20230105","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R25-20230105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/acr.22400","article-title":"Is spinal mobility in patients with spondylitis determined by age, structural damage, and inflammation?","volume":"67","author":"Calvo-Gutierrez","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R26-20230105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R27-20230105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.2008.103200","article-title":"Short-term changes in magnetic resonance imaging and disease activity in response to infliximab","volume":"69","author":"Bonel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R28-20230105","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R29-20230105","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2015-207786","article-title":"Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort","volume":"75","author":"Navarro-Compan","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20230105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R31-20230105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R32-20230105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R33-20230105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R34-20230105","first-page":"ii1","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68 Suppl 2","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R35-20230105","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","article-title":"Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab","volume":"54","author":"van der Heijde","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20230105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s100670050031","article-title":"Clinical assessment of spinal mobility measurements in ankylosing spondylitis: a compact set for follow-up and trials?","volume":"19","author":"Viitanen","year":"2000","journal-title":"Clin Rheumatol"},{"key":"R37-20230105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R38-20230105","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:24:02Z","timestamp":1672910642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":38,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022668","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}